synaffix.com
Synaffix | AboutSynaffix BV is a biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform.
http://www.synaffix.com/
Synaffix BV is a biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform.
http://www.synaffix.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.9 seconds
Synaffix BV
Floris Van Delft
Graa●●●●e 17
Ar●●em , Gelderland, 6846 JA
Netherlands
View this contact
Remo Natali
Graa●●●●e 17
Ar●●em , Gelderland, 6846 JA
Netherlands
View this contact
Remo Natali
Graa●●●●e 17
Ar●●em , Gelderland, 6846 JA
Netherlands
View this contact
BUY YOUR DOMAIN
14
YEARS
11
MONTHS
5
DAYS
WILD WEST DOMAINS, LLC
WHOIS : whois.wildwestdomains.com
REFERRED : http://www.wildwestdomains.com
PAGES IN
THIS WEBSITE
5
SSL
EXTERNAL LINKS
7
SITE IP
109.70.4.33
LOAD TIME
0.891 sec
SCORE
6.2
Synaffix | About | synaffix.com Reviews
https://synaffix.com
Synaffix BV is a biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform.
synaffix.com
Investors | Synaffix
http://www.synaffix.com/leadership/investors
News & Media. News & Media. News & Media.
Partnering | Synaffix
http://www.synaffix.com/partnering
News & Media. News & Media. News & Media. Our vision is to be the preferred technology partner, driving continued innovation in the field of ADCs for oncology that are both safer and more effective as well as easier to manufacture. We can generate nonclinical proof-of-concept (POC) material in just a few weeks. Further, we enable rapid development of ADC product candidates by our partners with a timeline to. IND filing as short as 12 months from preclinical POC. Director, Business Development.
Synaffix | Leadership
http://www.synaffix.com/leadership
News & Media. News & Media. News & Media. Peter van de Sande, MSc, MBA, MBL. Prior to joining Synaffix in 2011, Peter held various executive positions at CPS Color. Floris van Delft, PhD. Founder and Chief Scientific Officer. Sander van Berkel, PhD. Founder and Director, R&D Operations. Director, Business Development.
Board of Directors | Synaffix
http://www.synaffix.com/leadership/board-of-directors
News & Media. News & Media. News & Media. Konstantinos Efthymiopoulos, PhD, MBA. Simon Nebel, PhD, MBA. Since joining Aravis in 2001, Simon Nebel has participated in the financing of a number of life science companies and the M&A transactions of a number of Aravis portfolio companies. Most recently he was a co-founder of Aravis Energy I LP, the first Swiss Limited Partnership focused on renewable energy. Hakan Goker, PhD. Peter van de Sande, MSc, MBA, MBL.
News & Media | Synaffix
http://www.synaffix.com/news-media
News & Media. News & Media. News & Media. Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and Expands Its Scientific Advisory Board. July 20, 2016 /. Posted By : admin /. AMSTERDAM, THE NETHERLANDS — Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical […]. May 20, 2016 /. Posted By : admin /. San Diego, US.
TOTAL PAGES IN THIS WEBSITE
5
Portfolio - BioGeneration Ventures II | BioGeneration Ventures B.V.
http://www.biogenerationventures.com/portfolio/biogeneration-ventures-ii/_408____NL
BioGeneration Ventures II B.V. Acerta Pharma develops novel therapeutics in oncology and autoimmune diseases. Cristal Therapeutics www.cristaltherapeutics.com. BioGeneration Ventures II B.V. Cristal Therapeutics develops, a new class of nanomedicines based on its proprietary polymeric technologies with an optimized drug disposition and a more favorable tolerability profile. BioGeneration Ventures II B.V. Dezima Pharma develops a best in class CETP inibitor for the treatment of cardiovascular disease.
Portfolio - BioGeneration Capital Fund | BioGeneration Ventures B.V.
http://www.biogenerationventures.com/portfolio/biogeneration-capital-fund/_407____NL
BioGeneration Ventures II B.V. Acerta Pharma develops novel therapeutics in oncology and autoimmune diseases. Cristal Therapeutics www.cristaltherapeutics.com. BioGeneration Ventures II B.V. Cristal Therapeutics develops, a new class of nanomedicines based on its proprietary polymeric technologies with an optimized drug disposition and a more favorable tolerability profile. BioGeneration Ventures II B.V. Dezima Pharma develops a best in class CETP inibitor for the treatment of cardiovascular disease.
Portfolio | BioGeneration Ventures B.V.
http://www.biogenerationventures.com/portfolio/_388____NL
Acerta Pharma B.V. www.acerta-pharma.com. BioGeneration Ventures II B.V. Acerta Pharma develops novel therapeutics in oncology and autoimmune diseases. Arcarios B.V. www.arcarios.com. BioGeneration Ventures B.V. Arcarios develops novel therapeutics for bone and joint diseases. ArGEN-X B.V. www.argen-x.com. BioGeneration Ventures B.V. ArGEN-X employs a superior therapeutic antibody platform for the generation of human monoclonal antibodies. BioCeros B.V. www.bioceros.com. BioGeneration Ventures B.V. BioGe...
SynAffix verhuisd naar Pivot Park - ChemieNextChemieNext |
http://www.chemienext.nl/synaffix-verhuisd-naar-pivot-park
SynAffix verhuisd naar Pivot Park. Apr 14 • Chemie en gezondheid. Bull; 2231 Weergaves • Geen reacties op SynAffix verhuisd naar Pivot Park. SynAffix, sinds januari gevestigd op het Pivot Park. Voor meer informatie ga naar: www.synaffix.com. Over de auteur: Mariëlle Langereis. Mariëlle Langereis (1985) is sinds 2013 werkzaam op het gebied van kennisvalorisatie en innovatie. Daarvoor heeft ze een 4-jarig promotieonderzoek gedaan aan de Radboud Universiteit op het gebied van organische chemie. Hoe kun je w...
Sponsors
http://www.precisionbreastcancer.com/sponsors.html
BSP Pharmaceuticals S.p.A. Is a Contract Development Manufacturing Organization focused on development, clinical and commercial production and fully dedicated to anticancer products, without any potency limitation. BSP has a manufacturing plant located close to Rome, in Latina Scalo (LT), Italy and a commercial branch in Princeton, NJ (USA). The plant is a high containment manufacturing facility designed to achieve an Occupational Exposure Limit (OEL): 10 nanograms/m3. Our production area includes four s...
Precision: Breast Cancer conference in Boston 2017 | Neo-Synth
http://www.precisionbreastcancer.com/index.html
A GLOBAL PHARMA R&D SUMMIT. SCOPE OF THE MEETING. An exclusive, annual biopharma summit providing insights into the research and development of cutting edge treatments for Breast Cancer and a networking forum for precision medicine leaders in this space. Breast Cancer is the most commonly occurring cancer in women, and is also the second leading cause of cancer death. Receives the largest amount of spending across all cancer types, and represents the largest opportunity for developers. VP, Director, Head.
TOTAL LINKS TO THIS WEBSITE
7
Page parking de votre nom de domaine | NAMEBAY.COM
Enregistrer nom de domaine. Transférer nom de domaine. Renouveler nom de domaine. Alerte à la création. FAQ nom de domaine. Ce nom de domaine a été réservé par l’un de nos clients. Ajouter un compte email. Accéder à mon webmail. Devenir revendeur de nom de domaine. Consulter l'actualité de l'industrie des noms de domaine. Ce service de page d'attente vous est proposé par NAMEBAY.COM.
Synafel Accueil
Synafel Enseigne signalétique enseignes syndicat. Mot de passe :. La référence des pro de l'enseigne et de la signalétique. Fédération européenne de l'enseigne et de la signalétique. Pour tout savoir sur l'ESF. Rendez-vous sur son nouveau site internet. Visible #12 vient de paraitre :. Actus, interviews, nouveautés, événements, culture, tendances. Découvrez le dossier de ce trimestre : L'ART D'EMBALLER EN MOINS D'UNE MINUTE. Et de nombreux autres articles. Ecrivez à celine@656editions.net.
Page parking de votre nom de domaine | NAMEBAY.COM
Enregistrer nom de domaine. Transférer nom de domaine. Renouveler nom de domaine. Alerte à la création. FAQ nom de domaine. Ce nom de domaine a été réservé par l’un de nos clients. Ajouter un compte email. Accéder à mon webmail. Devenir revendeur de nom de domaine. Consulter l'actualité de l'industrie des noms de domaine. Ce service de page d'attente vous est proposé par NAMEBAY.COM.
Page parking de votre nom de domaine | NAMEBAY.COM
Enregistrer nom de domaine. Transférer nom de domaine. Renouveler nom de domaine. Alerte à la création. FAQ nom de domaine. Ce nom de domaine a été réservé par l’un de nos clients. Ajouter un compte email. Accéder à mon webmail. Devenir revendeur de nom de domaine. Consulter l'actualité de l'industrie des noms de domaine. Ce service de page d'attente vous est proposé par NAMEBAY.COM.
SYNAFETPCI-ENSEIGNEMENT TECHNIQUE PROFESSIONNEL
Jeudi 13 août 2015. Eͪxcuse me darling :-P. 97;re u si͊ngle? I͑m nö́t, but i need some d֛@ck on tٙhe side !! 30/f with a cur͙vͧy bod̜y and nice legs . want to h00kup? :-P. 77;y usern͛ame is Sharon̟a͞1976. 77;y page is hereͣ: http://Sharonagic.WildHookupAlert.pw. Mercredi 12 août 2015. 5 New LocalSlut Notifications. U֒n͕believٌable pْe֤cke֚r. My scr̭eenname iͬs Engًracia. My page is he̠re: http:/ Engraciahmc.WildHookupAlert.pw. Dimanche 9 août 2015. Want to f%ck Yoshiko tonight. Mardi 4 août 2015. I w...
Synaffix | About
News & Media. News & Media. News & Media. Synaffix enables ADCs for oncology that are both safer and more effective as well as easier to manufacture. Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform. Our antibody conjugation technology, GlycoConnect , enables the design of complex biological drugs without the need for prior genetic modification and with specificity a...
palpitacje mózgu czyli wdycham pranę
Palpitacje mózgu czyli wdycham pranę. O wakacjach - fotorelacja. Byliśmy tam, gdzie zawsze, więc bez zbędnych słów - było tak:. Linki do tego posta. O powrocie do pracy. Było zimno, wietrznie, deszczowo i przepięknie - jak zwykle nad Bałtykiem, bo ja po prostu bardzo lubię Bałtyk. Dokumentację zdjęciową obiecuję wrzucić wkrótce. Tymczasem jednak nadrabiam zaległości. Opowiem Wam więc o kolejnej rzeczy, którą bardzo lubię, czyli o mojej pracy. PS Nie ogarnęłam się jeszcze w nowej pracy na tyle, żeby znale...
Synafia's Blog | Just another WordPress.com weblog
Just another WordPress.com weblog. Grudzień 15, 2009. Welcome to WordPress.com. This is your first post. Edit or delete it and start blogging! Blog na WordPress.com. Follow “Synafia's Blog”. Otrzymuj każdy nowy wpis na swoją skrzynkę e-mail. Stwórz stronę przy użyciu WordPress.com.
SynafiDK's blog - Blog de SynafiDK - Skyrock.com
24/02/2016 at 12:34 AM. 25/02/2016 at 12:46 AM. Subscribe to my blog! Don't forget that insults, racism, etc. are forbidden by Skyrock's 'General Terms of Use' and that you can be identified by your IP address (66.160.134.62) if someone makes a complaint. Please enter the sequence of characters in the field below. Posted on Thursday, 25 February 2016 at 12:46 AM. Post to my blog. Here you are free.
:::SYNAFIG:::
PARTENARIAT SYNAFIG CENTRE DE GESTION INTEGREE DU MINISTERE DES TRANSPORTS Pour les NOUVEAUX PERMIS DE CONDUIRE ET LES NOUVELLES CARTE GRISE. A propos du synafig. Programme immobilier les oliviers. Voir toute la galerie. VISITE GUIDÉE DE LA POLYCLINIQUE DES 2 PLATEAUX. PARTENARIAT SYNAFIG CENTRE DE GESTION INTEGREE DU MINISTERE DES TRANSPORTS. Voir tous les articles. Jeu 1 Jan 1970, 00:00. RESEAU ASCOMA ABIDJAN ET INTERIEUR. Voir tous les articles. A propos de SYNAFIG. Inscrivez vous à la newsletter.
Synaffix | About
News & Media. News & Media. News & Media. Synaffix enables ADCs for oncology that are both safer and more effective as well as easier to manufacture. Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform. Our antibody conjugation technology, GlycoConnect , enables the design of complex biological drugs without the need for prior genetic modification and with specificity a...
SOCIAL ENGAGEMENT